Early predictors of colchicine resistance in familial Mediterranean fever

• Published in: Modern rheumatology 2023-07, Vol.33 (4), p.830-835
• Main Authors: Mosad Mosa, Doaa, Shokry, Doaa, Ahmed, Dina B, Sobh, Ali
• Format: Article
• Language: English
• Subjects: Child; Colchicine - therapeutic use; Familial Mediterranean Fever - diagnosis; Familial Mediterranean Fever - drug therapy; Familial Mediterranean Fever - genetics; Genotype; Humans; Mutation; Myalgia - drug therapy; Pyrin - genetics
• ISSN: 1439-7595; 1439-7609
• DOI: 10.1093/mr/roac068

ABSTRACT Objective To explore early features that can predict colchicine resistance in familial Mediterranean fever (FMF) patients. Methods It included FMF cases who fulfilled the Yalcinkaya–Ozen criterion and were on colchicine for at least 6 months. Data were collected from medical files and interpreted with respect to clinical parameters, incluing the auto-inflammatory diseases activity index (AIDAI) and FMF severity score. FMF50 score assessed the treatment response. Laboratory findings and genetic analysis of Mediterranean fever (MEFV) mutations were evaluated according to the standard technique. Patients were classified into two groups according to their response to colchicine. Both groups were compared, and significant variables were entered into a logistic regression model to detect independent predictors. The diagnostic accuracy of these predictors was assessed using the receiver operating characteristic curve. Results In all, 120 FMF children were included. After the exclusion of 16 non-compliant patients (13.3%), colchicine responders were 66 (63.4%) (group I) and colchicine-resistant cases (group II) were 38 (36.5%). The fever duration after colchicine, number of attacks before/after colchicine, skin rash/erysipelas-like erythema, myalgia/protracted febrile myalgia, AIDAI before/after treatment, FMF severity score, and the maximum colchicine dose were higher in group II. Furthermore, high C-reactive protein and neutropenia were frequent in group II. However, different MEFV mutations, including M694V were similar between the two groups. Eight variables were detected in the regression analysis model, and independent predictors were utilized to generate a scoring model. Conclusion This study constructed a prediction model for colchicine nonresponse based on clinical and laboratory profiles. This model will be valuable for the treatment decisions of FMF children.